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Abstract
Introduction: Pseudomonas aeruginosa is a frequent cause of ventilator-acquired pneumonia (VAP). Candida
tracheobronchial colonization is associated with higher rates of VAP related to P. aeruginosa. This study was
designed to investigate whether prior short term Candida albicans airway colonization modulates the pathogenicity
of P. aeruginosa in a murine model of pneumonia and to evaluate the effect of fungicidal drug caspofungin.
Methods: BALB/c mice received a single or a combined intratracheal administration of C. albicans (1 × 10
5 CFU/
mouse) and P. aeruginosa (1 × 10
7 CFU/mouse) at time 0 (T0) upon C. albicans colonization, and Day 2. To
evaluate the effect of antifungal therapy, mice received caspofungin intraperitoneally daily, either from T0 or from
Day 1 post-colonization. After sacrifice at Day 4, lungs were analyzed for histological scoring, measurement of
endothelial injury, and quantification of live P. aeruginosa and C. albicans. Blood samples were cultured for
dissemination.
Results: A significant decrease in lung endothelial permeability, the amount of P. aeruginosa, and bronchiole
inflammation was observed in case of prior C. albicans colonization. Mortality rate and bacterial dissemination were
unchanged by prior C. albicans colonization. Caspofungin treatment from T0 (not from Day 1) increased their levels
of endothelial permeability and lung P. aeruginosa load similarly to mice receiving P. aeruginosa alone.
Conclusions: P. aeruginosa-induced lung injury is reduced when preceded by short term C. albicans airway
colonization. Antifungal drug caspofungin reverses that effect when used from T0 and not from Day 1.
Introduction
Ventilator-associated pneumonia (VAP) occurs in a con-
siderable proportion of patients undergoing mechanical
ventilation and is associated with substantial morbidity,
a two-fold increase in mortality rate, and excess cost [1].
Tracheobronchial colonization (TBC) and duration of
mechanical ventilation are the two most important risk
factors for VAP [2,3]. Pseudomonas aeruginosa is one of
the most frequent causative microorganisms of VAP
[2-4]. Several studies have reported the presence of Can-
dida species in the airway specimens of immunocompe-
tent ventilated patients [5,6]. Candida TBC occurs in
17% to 28% of ICU patients receiving mechanical venti-
lation for more than 48 hours [7-9]. Although the rela-
tionship between tracheal biofilm and VAP is based on
one small observational study, P. aeruginosa is the most
common pathogen retrieved from endotracheal tube
biofilm in patients with VAP [10]. P. aeruginosa and C.
albicans coexist predominantly as biofilms rather than
as free-floating (planktonic) cells on abiotic medical
devices (catheters and prostheses) [11,12].
The question of their interplay has been addressed by
several experimental and clinical studies. So far, in vitro
studies suggest that the interaction between C. albicans
and P. aeruginosa is likely to be antagonistic. When
mixing in vitro cultures, P. aeruginosa is involved in kill-
ing C. albicans filaments associated with biofilm forma-
tion [13]. Additionally, quorum-sensing signaling
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hyphae transition [14]. The relative C. albicans hyphal-
binding affinity within biofilm is reported to be lower
for P. aeruginosa than for Staphylococcus aureus [15]. In
contrast, a synergistic relationship is described in vivo
with a recent study showing that C. albicans TBC facili-
tates P. aeruginosa pneumonia occurrence in a rat
model [16]. A recent clinical study suggested an interac-
tion between C. albicans and P. aeruginosa [8]. The
authors identified Candida spp. tracheobronchial coloni-
zation as an independent risk factor for P. aeruginosa
pneumonia. No cause-and-effect relationship was
demonstrated in that study. In addition, Candida spp.
tracheobronchial colonization and P. aeruginosa pneu-
monia could both be a consequence of prior antibiotic
treatment. Further, the median duration of mechanical
ventilation in that study was 13 days. Therefore, the
results could not be generalized to patients with shorter
duration of mechanical ventilation. Another recent preli-
minary case-control study suggested that antifungal
treatment might be associated with reduced risk for
VAP or TBC related to P. aeruginosa [9], although no
definite conclusion can be drawn from this observational
retrospective single-center study including a small num-
ber of patients.
The study of P. aeruginosa and C. albicans interac-
tions in the respiratory tract aims at more effectively
understanding the balance between microbial ecology
and bacteria-related pathogenesis. This issue has major
environmental and medical consequences. The present
study proposes to investigate P. aeruginosa-related lung
injury in mice previously colonized with C. albicans and
to evaluate the impact of caspofungin antifungal
treatment.
Materials and methods
Animals
BALB/c mice (20 to 25 g) purchased from Charles River
Laboratories (Domaine des Oncins, L’Arbresle, France)
were housed in a pathogen-free unit of the Lille Univer-
sity Animal Care Facility and allowed food and water ad
lib. All experiments were performed with the approval
of the Lille Institutional Animal Care and Use
Committee.
Growth conditions for bacterial and yeast strains
The wild type strain Pseudomonas aeruginosa PAO1 was
grown in Luria-Bertani medium at 37°C for 16 h and
was centrifuged at 3,000 × g for 10 minutes. The bacter-
ial pellets were washed twice and diluted in an isotonic
saline solution to obtain an optical density of 0.63 to
0.65 nm determined by spectrophotometry [17].
The reference strain C. albicans SC5314 was main-
tained at 4°C on Sabouraud dextrose agar (SDA) [18].
For the study, cell of broth test isolates were grown in
SDA at 37°C in a shaking incubator for 18 h.
Mice infection
Mice were infected by direct intratracheal inoculation
under short anaesthesia with inhaled sevoflurane (Ser-
vorane™, Abbott, Queenborough, UK) as previously
described [17]. For each mouse, 50 μlo ff u n g a lo rb a c -
terial suspension containing 2 × 10
6 or 2 × 10
7 or 2 ×
10
8 colony-forming units (CFU)/ml of yeasts or 2 × 10
8
CFU/ml of bacteria respectively, was instilled. Control
mice received 50 μl of sterile saline solution.
Treatment with caspofungin
Caspofungin (Merck & Co. Inc., Whitehouse Station, NJ,
USA) was injected intraperitoneally once daily either
from T0 or from 24 h post-C. albicans challenge. The
full recommended dose of 1 mg/kg was administered
the first day of treatment and then 0.8 mg/kg was admi-
nistrated on Days 2, 3, and 4.
Quantitative blood culture and pulmonary bacterial and
fungal loads
For bacterial blood culture, 100 μl of blood was plated
on bromocresol purple (BCP) agar plates for 24 h at 37°
Ct oa l l o wf o rP. aeruginosa growth. In co-infected
groups, BCP agars were treated with 50 μg per plate of
caspofungin. For fungal blood culture, the same amount
was plated on yeast peptone dextrose (YPD) agar plates
containing 1% yeast extract, 1% peptone, 2% D-glucose
and 500 mg/l amikacin sulphate and incubated for 48 h
at 37°C to allow for C. albicans growth.
For quantification of lung bacterial loads, lungs were
removed after exsanguination via intracardiac puncture
and homogenized in 0.9 ml of sterile isotonic saline solu-
tion. Viable bacteria were counted after serial dilutions of
100 μL of lung homogenate on BCP agar plates for 24 h at
37°C to allow for P. aeruginosa growth. Similarly, another
100 μL of lung homogenate was plated on YPD plates for
48 h to allow for C. albicans growth. In co-infected
groups, agar was treated with caspofungin or amikacin.
In vivo quantification of acute lung injury: alveolar-
capillary barrier permeability
125I-albumin was injected as a vascular protein tracer
and its leakage across the endothelial barrier and accu-
mulation in the extravascular spaces of the lungs was
measured using a previously described permeability
index [19]. More details are provided in the Additional
file 1.
Determination of histological score
At Days 2 and 4, the lungs were removed and fixed
overnight in 4% paraformaldehyde-acid and embedded
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thick) were stained with hematoxylin and eosin stain
(Sigma-Aldrich Europe, Saint-Quentin Fallavier, France)
and periodic acid Schiff. Two independent blinded
investigators graded the inflammation score. The degree
of peribronchial and perivascular inflammation was eval-
uated on a subjective scale of 0 to 3, as described else-
where [20].
Fluorescence staining of C. albicans in situ
Paraffin-embedded lung sections were stained with
either the monoclonal antibody (mAb) 5B2 or the
galenthus nivalis lectin [21,22] and examined by immu-
nofluorescence microscopy (Leica Microsystems AG,
Heerbrugg, Switzerland).
Experimental groups
Animals were randomly assigned to the following
groups: Ca: mice infected with 1 × 10
5 CFU of C. albi-
cans at T0 and sacrificed at Day 2 or 4; Pa: mice
infected with 1 × 10
7 CFU of P. aeruginosa at Day 2
and sacrificed at Day 4; CaPa: mice infected with 1 ×
10
5 CFU of C. albicans at T0, infected with 1 × 10
7
CFU of P. aeruginosa at Day 2 after infection by C. albi-
cans, and sacrificed at Day 4; CaPaCasp0 and CaPa-
Casp1: mice infected with 1 × 10
5 CFU of C. albicans at
T0, treated with caspofungin from T0 or from Day 1 to
Day 4, infected with 1 × 10
7 CFU of P. aeruginosa at
Day 2 after infection by C. albicans, and sacrificed at
Day 4. The experimental design is further detailed in
Table 1. The sample size was four (microbial count
assay), five (mortality assay), and eight animals (perme-
ability index assay) per group. Each experiment was per-
formed in duplicate.
Statistical analysis
Mortality rates were compared between groups by using
the log rank test with Kaplan-Meier analysis. Data were
analyzed by Kruskal-Wallis one-way analysis of variance
test using Dunn’s method to compare differences
between groups (GraphPad Prism, v5.0, La Jolla, Califor-
nia, USA). Data are expressed as means ± standard
error of the mean (SEM). P-values below 0.05 were con-
sidered significant.
Results
C. albicans tracheobronchial colonization in mice and
dose-dependent pathophysiological effects
To set up the model of tracheobronchial colonization,
mice were challenged with three doses of C. albicans (1
×1 0
5,1×1 0
6,a n d1×1 0
7 CFU per mouse). At Day 2,
mortality rates were 0%, 20%, and 100% respectively,
indicating a dose-dependent effect of C. albicans.A t
D a y2 ,a f t e rad o s eo f1×1 0
5 and 1 × 10
6 CFU per
mouse, the amount of live C. albicans in lungs was
diminished by 2.5 logs for both doses (Figure 1A) and
none of them induced positive fungal blood cultures
(data not shown). At that time, the lung endothelial per-
meability was similar in the control saline solution
groups and the 1 × 10
5 CFU group (Figure 1B). On the
contrary, the efflux of the protein tracer was statistically
greater for the 1 × 10
6 CFU group than for the control
saline solution groups (P < 0.01). Regarding lung histo-
pathology, an increase of inflammatory cell infiltration
within bronchiole and in the surrounding lung parench-
yma was observed at Day 2 in the lung of mice receiving
1×1 0
5 C. albicans cells on the photomicrographs in
comparison to control mouse lungs followed by full
recovery at Day 4. Immunostained lung sections from
mice challenged with C. albicans showed the presence
of C. albicans blastoconidia (absence of hyphae or pseu-
dohyphae). Images of lung histopathology after C. albi-
cans TBC in mice are provided in Additional file 2.
Effect of prior C. albicans tracheobronchial colonization
on P. aeruginosa pneumonia
We next addressed the issue whether prior C. albicans
colonization in the lungs has an impact on the P. aeru-
ginosa pathogenicity. When recording mortality over the
course of four days post-infection, prior C. albicans air-
way colonization did not affect survival rate in case of
subsequent P. aeruginosa infection (Figure 2A), although
a trend toward an increased mortality was noted in the
Pa group, but did not reach a statistical significance.
Table 1 Experimental design of the study
Time(s) of infection Bacterial and yeast delivery (CFU/mouse) Caspofungin treatment Day(s) of sacrifice
Ctr / Saline solution none Day 2, Day 4
Ca T0 1 × 10
5 C. albicans none Day 2, Day 4
Pa Day 2 1 × 10
7 P. aeruginosa none Day 4
CaPa T0, Day 2 T0: 1 × 10
5 C. albicans
d2: 1 × 10
7 P. aeruginosa
none Day 4
CaPaCasp0 T0, Day 2 T0: 1 × 10
5 C. albicans
d2: 1 × 10
7 P. aeruginosa
T0 to Day 4 Day 4
CaPaCasp1 T0, Day 2 T0: 1 × 10
5 C. albicans
d2: 1 × 10
7 P. aeruginosa
Day 1 to 4 Day 4
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efflux of the protein tracer in the CaPa-group was statis-
tically greater than both the control- and Ca-groups (P
< 0.01) but significantly lower than in the Pa-group (P <
0.001) (Figure 2B). In lung cultures at Day 4, the Pa-
group showed a significant higher amount of live bac-
teria in lungs in comparison to the CaPa-group (P <
0.001) indicating that previous C. albicans airway colo-
nization promoted the clearance of P. aeruginosa from
the lungs (Figure 3). Also, in blood cultures at Day 4, P.
aeruginosa detection was negative in the CaPa-group
whereas they were still positive in 25% of the cases in
the Pa-group (Table 2). No further C. albicans systemic
dissemination was evidenced in the CaPa-group. The
onset of P. aeruginosa pneumonia after C. albicans
colonization did not affect lung C. albicans growth,
which remained negative during the study period.
An important inflammatory cell infiltration within
bronchiole and in the surrounding lung parenchyma
was observed in mice receiving P. aeruginosa as evi-
denced by the histological score of lung sections (Figure
4A). Conversely, the CaPa-group had a significantly
lower score of pathological lesions than the Pa-group on
the histological score of lung sections (P < 0.05) (Figure
4A). Lung immunostaining at Day 4 showed the pre-
sence of C. albicans blastoconidia exclusively (Figure
4C-Images a and b). Together, our results suggest that
C. albicans colonization prior to P. aeruginosa infection
decreases the P. aeruginosa bacterial load and minimizes
the lung lesions.
Effect of antifungal treatment on C. albicans interference
with P. aeruginosa pneumonia
Antifungal caspofungin has been used to test whether it
might reverse the effect of C. albicans airway coloniza-
tion on subsequent P. aeruginosa pneumonia. The treat-
ment was initiated upon infection at T0 or after a delay
at Day 1 post-colonization. The fungicidal effect of
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Figure 1 C. albicans tracheobronchial colonization in mice and
dose-dependent pathophysiological effects. A. C. albicans
clearance from lungs. C. albicans loads in lungs two days after the
intratracheal instillation of 1 × 10
5 and 1 × 10
6 CFU/mouse. CFU
were counted on YPD plates. The data are means ± standard error
(SE) (indicated by error bars). n = 5 mice per group. B. Effect of C.
albicans on alveolar-capillary barrier permeability. Evaluation of
endothelial permeability (EP) of the alveolar-capillary barrier to
125I-
labeled bovine serum albumin two days after the intratracheal
instillation of 1 × 10
5 and 1 × 10
6 CFU/mouse of C. albicans. The
data are means ± SE (indicated by error bars). n = 5 mice per
group.
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Figure 2 Effect of previous C. albicans tracheobronchial
colonization on P. aeruginosa-related lung injury. A. BALB/c
mice survival. Effect of C. albicans (Ca), P. aeruginosa (Pa), and P.
aeruginosa after C. albicans (CaPa) on mouse survival during four
days after intratracheal instillation of a dose of 1 × 10
5 CFU/mouse
of C. albicans at T0 and of 1 × 10
7 CFU/mouse for P. aeruginosa
administrated at Day 2 post-colonization. n = 8 mice per group. B.
Effect of C. albicans and P. aeruginosa on alveolar-capillary barrier
permeability. Evaluation of endothelial permeability (EP) of the
alveolar-capillary barrier to
125I-labeled bovine serum albumin four
days after the intratracheal instillation of a saline solution (Ctr) and
in Ca, Pa, CaPa groups. The data are means ± SE (indicated by error
bars). n = 8 mice per group.
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D a y2a n dn op o s i t i v ef u n g a lc ultures were collected in
both the CaCasp0- and the CaCasp1-groups (data not
shown). Furthermore, the lack of impact of caspofungin
on endothelial permeability was also confirmed at Day 1
after a single intraperitoneal injection of 1 mg/kg of cas-
pofungin in control saline solution-instilled mice (data
not shown). Caspofungin administration from T0
reversed the effect of previous airway colonization by C.
albicans on P. aeruginosa-induced lung injury (Figure
5). Thus, when the antifungal is administered early the
lung injury induced by P. aeruginosa persists and the
endothelial permeability showed by means of protein
tracer leak is enhanced to the level of the Pa-group. In
contrast, caspofungin administration from Day 1 did not
reverse the C. albicans effect as an equal amount of pro-
tein efflux tracer was observed in the Ca- and CaPa-
groups and was still significantly different from the Pa-
group (P < 0.001).
Regarding lung bacterial counts at Day 4, the effect of
caspofungin was different depending on the time of
administration (Figure 3). Administration from T0 (the
CaPaCasp0-group) significantly abolished the decrease
of positive specimens observed in the CaPa-group (P <
0.001). Conversely, delayed administration from day 1
(CaPaCasp1-group) resulted in collecting a roughly simi-
lar amount of live P. aeruginosa in lungs than in the
CaPa-group creating a significant difference with the
CaPaCasp0-group (P < 0.01).
Discussion
The present study was designed to determine the contri-
bution of C. albicans airway colonization to P. aerugi-
nosa pathogenicity in immunocompetent mice. Our
results indicate that prior short-term C. albicans airway
colonization reduced P. aeruginosa-induced lung injury
and the amount of live P. aeruginosa in lungs. This
effect is reversed by fungicidal drug caspofungin when
initiated concomitantly to C. albicans infection.
T h ep r e r e q u i s i t et ot h es t u d yw a st h es e t - u po ft r a -
cheobronchial colonization by C. albicans according to
the definition of colonization, which is the presence of a
pathogen that does not cause damages on the lung par-
enchyma. The dose of 1 × 10
5 CFU of C. albicans per
mouse matched with this criterion as no invasive disease
occurred. After P. aeruginosa infection, a trend toward a
higher survival rate in the C. albicans-colonized mice
was observed. This result is consistent with data com-
paring groups of mice instilled simultaneously with P.
aeruginosa and C. albicans or with P. aeruginosa alone
showing a significant difference of survival in favor of
the C. albicans-colonized group at Day 7 [23]. Then, it
was found that previous C. albicans airway colonization
was associated with an increase in lung P. aeruginosa
clearance compared to the non-colonized-group. These
data differ from the previous study, which did not detect
a significant decrease in quantitative bacterial burden in
the group receiving simultaneous administration of C.
albicans along with P. aeruginosa [ 2 3 ] .H o w e v e r ,a
major difference is that bacterial loads were recorded
early after the co-infection between 3 and 20 h. Another
study, which addressed the issue of prevalence of P. aer-
uginosa pneumonia in rats colonized by C. albicans,
evaluated the quantitative bacterial cultures of P. aerugi-
nosa in rat lungs at 48 h post-infection [16]. Subsequent
to C. albicans colonization obtained by intratracheal
instillation (2 × 10
6 CFU per rat three days in a row), a
low dose of P. aeruginosa (1 × 10
4 CFU per rat) was
delivered at Day 2 post-colonization. The bacterial bur-
den was significantly higher at 48 h in rats instilled with
C. albicans before P. aeruginosa compared to rats
Pa
CaPa
CaPaCasp0
CaPaCasp1
100
101
102
103
104
105
p < .001
p < .001
p < .001 p < .01
Day 4
C
F
U
/
m
L
 
l
u
n
g
 
h
o
m
o
g
e
n
a
t
e
Figure 3 P. aeruginosa CFU count in lungs.L i v eP. aeruginosa
count in lung homogenates (CFU/ml) at Day 4 in Ctr, Ca, Pa, CaPa
groups and caspofungin-treated group at the dose of 1 mg/kg the
first day and 0.8 mg/kg the following days until Day 4, from T0
(CaPaCasp0) or from Day 1 (CaPaCasp1). The data are means ± SE
(indicated by error bars). n = 4 mice per group.
Table 2 Growth of P. aeruginosa and C. albicans strains in
blood and effect of caspofungin
Bacterial growth Fungal growth
Ca / 0/8
Pa 2/8* /
CaPa 0/8 0/8
CaPaCasp0 0/8 0/8
CaPaCasp1 0/8 0/8
CFU were detected on BCP and YPD plates at Day 4. Positive samples are
shown in the table. *CFU counts for positive samples were 20 and 40 CFU/ml.
n = 4 mice per group.
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cans before P. aeruginosa. Contrary, in our experimental
model, P. aeruginosa dissemination in the bloodstream
showed a trend toward a decrease in the case of prior
C. albicans colonization. Although bacterial dissemina-
tion is multifactorial depending on the magnitude of
alveolar-capillary barrier injury [24] as well as the strain
virulence and the size of the inoculum [25], the decrease
was most likely due to the decrease of alveolar-capillary
barrier injury since the P. aeruginosa strain used and
the size of the inoculum administrated were identical in
both groups. Regarding histolopathologic results, the
inflammation score decreased in the case of previous C.
albicans airway colonization in comparison to P. aerugi-
nosa infection alone suggesting that primary immune
activation could reduce P. aeruginosa pathogenicity.
This observation was consistent with a decrease in P.
aeruginosa lung loads and a decrease in the lung
permeability index in the CaPa group in comparison to
the Pa group. These results differ from a study pre-
viously mentioned which concluded that previous C.
albicans colonization lowered the threshold of P. aerugi-
nosa load necessary to induce parenchymal injury since
in rats given C. albicans,h i s t o l o g i ca s p e c to fP. aerugi-
nosa pneumonia was significantly more frequent than in
controls or ethanol-killed C. albicans rats [16]. Overall,
the results may differ between mice and rats, and
between different strains of P. aeruginosa owing to dif-
ferential susceptibility to pneumonia.
In the second part of this study, the influence of fun-
gicidal caspofungin was tested. The use of caspofungin
aimed at detecting a difference between colonization
with live or killed C. albicans. For that purpose, two tar-
get times for treatment initiation were chosen, from T0
or from Day 1. Regarding the alveolar-capillary barrier
injury, the use of caspofungin resulted in distinct effects:
(a)
(b)
Figure 4 Lung histopathology after sequential infection with C. albicans and P. aeruginosa in mice. A. Histological score of lung sections
from BALB/c mice on Day 4. Peribranchiol and perivascular lung inflammation in mice was measured by two independent blinded examiners.
Data are expressed as mean ±SE for each group. P < 0.05 for CaPa vs Pa mice. B. Immunofluorescence and periodic acid Schiff staining for C.
albicans localization in lungs of BALB/c mice on Day 4. (a) Representative section of lung from mice challenged with both C. albicans and P.
aeruginosa stained with fluorescent galenthus nivalis lectin (GNL) specific for terminal a-D-mannosyl, preferentially a-1,3 residues of C. albicans.
The scale bars represent 10 μm. (b) Lung section from mouse receiving C. albicans and P. aeruginosae stained with PAS (periodic acid Schiff). The
scale bars represent 5 μm.
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when initiated at T0 or maintenance of the decrease in
the protein tracer leakage when initiated at Day 1. The
difference observed between the T0- and the Day 1-trea-
ted group suggests that the viability and/or the growth
of C. albicans makes a difference in reducing the magni-
tude of alveolar-capillary barrier injury.
Overall, these results raise three hypotheses: first, a
competitive effect regarding the adhesion of the patho-
gens to lung epithelial surface. Indeed, they both use
ligands to recognize the glycoconjugates at the surface
of epithelial cells [26,27]. Recently, it has been demon-
strated that P. aeruginosa lectins LecA and LecB, which
are involved in adhesion to epithelial cells, contribute to
P. aeruginosa-induced lung injury [17]. The neutraliza-
tion of these lectins by the administration of specific
lectin inhibitors was remarkably effective in improving
lung injury. C. albicans adherence to host tissue is con-
trolled by the ALS (agglutinin-like sequence) gene family
which encodes a group of glycosyl-phosphatidyl-inositol
(GPI)-linked cell surface proteins that function as adhe-
sins that bind to the cell surface [28]. The second
hypothesis is a bactericidal effect mediated by higher-
inducible lung mucosal innate response by live C. albi-
cans. This hypothesis is supported by the decrease in
inflammation score in case of previous C. albicans
airway colonization in comparison to P. aeruginosa
infection alone, and by the fact that T0 caspofungin
treatment resulted in a higher rate of bacterial growth.
Finally, C. albicans produces farnesol, a cell-to-cell sig-
naling molecule that could act as a quorum-sensing
antagonist of P. aeruginosa [14,29]. The addition of far-
nesol to cultures of P. aeruginosa leads to decreased
production of the Pseudomonas quinolone signal (PQS)
and the PQS-controlled downstream virulence factor,
pyocyanin [30]. Furthermore, it has been shown that the
C. albicans farnesol has also the ability to inhibit
swarming motility in P. aeruginosa cystic fibrosis clinical
isolates [31]. All together, the reduction in PQS-pyocya-
nin production and swarming mobility may also have
implications for the interaction between P. aeruginosa
and the host.
The present study has several limitations that pre-
vent extrapolating the results to the chronically colo-
nized and/or critically ill patients at risk for VAP.
First, the short term C. albicans colonization in the
model does not correctly reflect the situation of these
patients. Indeed, the amount of C. albicans in lungs
cannot be substantially sustained over time in immu-
nocompetent BALB/c mice, as already described else-
where [32]. Consequently, P. aeruginosa pneumonia
had to be generated only 48 hours after the prior fun-
gal colonization. The addition of a control experimen-
tal group testing the impact of killed C. albicans
would have been of interest to assess the need of live
C. albicans to produce the effects described. Concern
can also be raised regarding some in vitro data indicat-
ing a decrease of P. aeruginosa growth following expo-
sure to halogenated anesthetics [33], although it
occurred after several hours of exposure and has not
been investigated in vivo. The short duration of mutual
contact and interaction of C. albicans and P. aerugi-
nosa in the airways (48 h) represents another potential
bias of the present study. Furthermore, a dose/effect
study testing various doses of P. aeruginosa to generate
pneumonia could better document the in vivo
dynamics of bacterial-fungal interactions. Performing
microbial CFU counts in spleen and liver could better
assess microbial dissemination. Finally, this relation-
ship is studied in normal lungs and in the absence of
a n ya i r w a yp r o s t h e t i cd e v i c e, which largely promotes
microbial community networking [12].
Conclusions
The present results demonstrate that P. aeruginosa-
related lung injury is reduced when preceded by short
term C. albicans airway colonization. Regarding the
use of the antifungal drug caspofungin, reduced P. aer-
uginosa-related lung injury is reversed when the treat-
ment is initiated at T0, and maintained when the
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Figure 5 Effect of caspofungin on alveolar-capillary barrier
permeability. Evaluation of endothelial permeability (EP) of the
alveolar-capillary barrier to
125I-labeled bovine serum albumin at Day
4 in Ctr, Ca, Pa, CaPa groups and caspofungin-treated group at the
dose of 1 mg/kg the first day and 0.8 mg/kg the following days
until Day 4, from T0 (CaPaCasp0) or from Day 1 (CaPaCasp1). The
data are means ± SE (indicated by error bars). n = 8 mice per
group.
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Page 7 of 9treatment is started one day after the onset of C. albi-
cans colonization. The study illustrates the complex
relationships between fungi and bacteria consistently
with a number of other works in which cross-kingdom
interactions result in very different effects (from
synergy to antagonism). Additionally, the impact of
antifungal agents on the fungal-bacterial ecosystem is
poorly understood. Further in vitro and in vivo studies
are required using cell wall C. albicans extracts such
as glucans or mannans during P. aeruginosa infection
in order to better understand the molecular mechan-
isms involved.
Key messages
￿ In this study, murine P. aeruginosa-induced lung
injury measured at 48 h post-infection is reduced when
preceded by short term C. albicans airway colonization.
￿ Additionally, short-term C. albicans colonization
results in a reduction of the amount of P. aeruginosa in
murine lungs at 48 h post-infection.
￿ Using the fungicidal drug caspofungin upon C. albi-
cans colonization reverses these effects.
Additional material
Additional file 1: In vivo quantification of acute lung injury:
alveolar-capillary barrier permeability. Method of measurement of
alveolar-capillary barrier permeability.
Additional file 2: Lung histopathology after C. albicans
tracheobronchial colonization in mice. Supplemental figures of lung
histopathology at Day 2 post-infection with C. albicans
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